El sistema se apagará debido a tareas habituales de mantenimiento. Por favor, guarde su trabajo y desconéctese.
Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study)
PHAM-LEDARD, Anne
BoRdeaux Institute of onCology [Inserm U1312 - BRIC]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
BoRdeaux Institute of onCology [Inserm U1312 - BRIC]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
QUEREUX, Gaëlle
Immunology and New Concepts in ImmunoTherapy [INCIT]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Immunology and New Concepts in ImmunoTherapy [INCIT]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
DE VICQ DE CUMPTICH, Marine
Centre Hospitalier Universitaire Brugmann [Bruxelles] [CHU]
Institut Jules Bordet [Bruxelles]
Centre Hospitalier Universitaire Brugmann [Bruxelles] [CHU]
Institut Jules Bordet [Bruxelles]
GUENOVA, Emmanuella
Université de Lausanne = University of Lausanne [UNIL]
Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] [CHUV]
Université de Lausanne = University of Lausanne [UNIL]
Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] [CHUV]
ADAMSKI, Henri
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
BEYLOT-BARRY, Marie
BoRdeaux Institute of onCology [Inserm U1312 - BRIC]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
< Leer menos
BoRdeaux Institute of onCology [Inserm U1312 - BRIC]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Idioma
EN
Article de revue
Este ítem está publicado en
British Journal of Dermatology. 2024-04-25p. ljae153
Resumen en inglés
The results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly ...Leer más >
The results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly minimize the risk of adverse effects, costs, and resistance to mogamulizumab. Additionally, our study emphasizes that mogamulizumab rechallenge should be encouraged as first-choice for relapsing patients.< Leer menos
Centros de investigación